22nd International Congress of Endocrinology (ICE 2026)

  • 2026

Description

The 22nd International Congress of Endocrinology (ICE 2026) is dedicated to practical clinical application in the field of endocrinology as well as the future of endocrine science.

The 22nd International Congress of Endocrinology (ICE 2026) covers topics such as:

  • Bone
  • Adrenal
  • Diabetes / Diabetes Complications
  • Cardiometabolic
  • Growth Hormone
  • Endocrine Cancers
  • Obesity/Lipids
  • Health Systems/Care
  • Reproductive Health
  • Pituitary/Neuroendocrinology
  • Thyroid
  • Technology

The 22nd International Congress of Endocrinology (ICE 2026) might be held in 2026.

More Details

Prices:
10-750 Euro (Estimated)
Organizer:
Kenes Group, International Society of Endocrinology (ISE)
Website:

Future Events

Past Events

Important

Please, check "International Congress of Endocrinology (ICE)" official website for possible changes, before making any traveling arrangements

Event Categories

Health & Medicine: Endocrinology

Other Events with Similar Categories

Other Events with Similar Location or Organizer

Featured Conferences & Exhibitions

Articles / News / Press releases

Article content. Press on the above link to close

Introduction: Diabetes mellitus is a growing epidemic and is the most common cause of chronic kidney disease and liver failure. Therefore, there is an urgent need to develop more effective medication-assisted treatments.

Methods: In this study, forty female mice were divided into eight groups with five animals in each. Type 1 diabetes mice models was established using multiple low-dose alloxan, and the diabetic mice were treated with three doses of dimethyl fumarate (DMF) i.e low, medium, and high viz. 20, 40 and 80 mg/kg, respectively for a period of 21 days. Then, specific test were done to evaluate blood biochemical parameters, oxidative stress markers, inflammatory cytokine, and histopathological changes in mice kidney and liver.

Results: Diabetic liver and kidney tissue showed marked dilation of bile ducts, tubules, infiltration, and inflammation. In addition, nuclear factor erythroid-2 related factor 2 (Nrf2) and its downstream effectors (Sirt1) were suppressed in these two diabetic tissues (p< 0.001). On the contrary, diabetic mice treated with DMF showed improvement in oxidative stress indices, inflammation, and this with increased Nrf2 and Sirt1 activation (p< 0.001).

Conclusion: Collectively, it can be concluded that the role of DMF as a blood sugar reducer and improvement of diabetes complications is very significant, likely via reducing activation of pro-inflammatory cytokines function. Although, some contradictory effects of inflammatory factors were observed in kidney and liver tissues, but overall, the therapeutic combination of DMF and metformin (MET) has a good hepato-renal protective ability in alloxan-induced diabetic mice model.